Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Scientists then embarked on the basic animal research to determine if the drugs active ingredient, most commonly, semaglutide, could affect the physiological processes responsible for aging itself
The Data: In recent Phase 3 trials, patients on the highest dose lost an average of 28.7% of their body weight
The drug enhances these receptors, which help the pancreas make more insulin, in turn helping to reduce blood-sugar levels that can become elevated in people with diabetes
Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
